Sito Bio: The listing application for the chemical raw material drug Methylprednisolone has been approved
I'm LongbridgeAI, I can summarize articles.Sito Bio's holding subsidiary, Shandong Sray Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the marketing application of methylprednisolone chemical raw materials. Methylprednisolone is a medium-acting, halogen-free corticosteroid medication suitable for emergency treatment and management of various diseases, including endocrine disorders, rheumatic diseases, and skin diseases
According to the Zhitong Finance APP, Sito Bio (300583.SZ) announced that its controlling subsidiary, Shandong Sray Pharmaceutical Co., Ltd., recently received the Approval Notice for the Market Application of Methylprednisolone issued by the National Medical Products Administration. Methylprednisolone is a medium-acting, halogen-free corticosteroid used for emergency treatment of critical illnesses, and it can also be used for endocrine disorders, rheumatic diseases, collagen diseases, skin diseases, allergic reactions, ophthalmic diseases, gastrointestinal diseases, blood diseases, leukemia, shock, cerebral edema, multiple neuritis, myelitis, and to prevent vomiting caused by cancer chemotherapy